Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498909 | 0.93 | POLB (0.53) | TP53ALDH1A1GAAKDM4ETMPRSS4 | |
| SCHEMBL6101632 | 0.92 | MAPT (0.53) | TP53ALDH1A1GAAKDM4ELMNA | |
| SCHEMBL3496921 | 0.90 | TMPRSS4 (0.58) | TP53ALDH1A1GAAKDM4ETMPRSS4 | |
| SCHEMBL19627242 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GAALMNAKMT2APOLB | |
| SCHEMBL13698751 | 0.85 | TMPRSS4 (0.55) | TP53ALDH1A1GAAKDM4ETMPRSS4 | |
| SCHEMBL6099753 | 0.84 | MAPT (0.56) | ALDH1A1GAAKDM4ELMNAHPGD | |
| SCHEMBL6103190 | 0.84 | POLB (0.52) | ALDH1A1GAAKDM4ELMNAKMT2A | |
| SCHEMBL19612092 | 0.83 | ALDH1A1 (0.47) | ALDH1A1GAAKDM4ELMNAKMT2A | |
| SCHEMBL19612172 | 0.83 | SMN1; SMN2 (0.46) | TP53GAAKDM4EKMT2ANTRK1 | |
| SCHEMBL13189425 | 0.82 | KMT2A (0.58) | TP53ALDH1A1KDM4ELMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-109415363-B | Novel mitochondrial uncoupling agents for the treatment of metabolic diseases and cancer | 罗格斯，新泽西州立大学 | 2021-07-20 | — | — | CN | disclosed |
| EP-3458454-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Rutgers, The State University of New Jersey (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | AK2, PC, GLS2 | TP53 231/4885ALDH1A1 463/4885GAA 468/4885 |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | AK2, PC, GLS2 | TP53 263/4885ALDH1A1 446/4885GAA 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.